Back to top
more

Lipocine (LPCN)

(Delayed Data from NSDQ)

$8.24 USD

8.24
25,114

+0.49 (6.32%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $8.27 +0.03 (0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

Lipocine Inc. [LPCN]

Reports for Purchase

Showing records 81 - 100 ( 106 total )

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 81

06/30/2016

Company Report

Pages: 6

Price: 24.95

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 82

06/29/2016

Company Report

Pages: 7

CRL Issued on LPCN 1021 Over Its Dose-Adjustment Protocol

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 83

05/11/2016

Company Report

Pages: 9

Price: 24.95

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 84

05/10/2016

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 85

05/10/2016

Company Report

Pages: 7

Q1 Lower on Launch Prep, TLANDO (LPCN 1021) PDUFA June 28

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 86

04/04/2016

Company Report

Pages: 8

Price: 24.95

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 87

02/17/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 88

02/17/2016

Company Report

Pages: 11

Price: 24.95

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 89

02/16/2016

Company Report

Pages: 9

1107?s Progesterone Plasma > Makena; PT Up $4 to $40

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 90

01/04/2016

Company Report

Pages: 8

Enrollment of LPCN 1111, Potentially First Once-a-day TRT, Is Underway

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 91

11/17/2015

Company Report

Pages: 9

Price: 24.95

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 92

11/16/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 93

11/16/2015

Company Report

Pages: 8

Lack of AdCom Reduces LPCN 1021?s Regulatory Risk, as BD Season Begins

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 94

10/15/2015

Company Report

Pages: 9

Price: 24.95

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 95

09/01/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 96

08/31/2015

Daily Note

Pages: 4

NDA on LPCN 1021 Has Been Submitted

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 10.00

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 97

08/12/2015

Company Report

Pages: 6

2Q15 Generally Inline; As Lipocine Starts To Bulk Up.

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 98

08/12/2015

Company Report

Pages: 15

Price: 24.95

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 99

07/31/2015

Company Report

Pages: 15

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Lipocine Inc.

Industry: Medical - Drugs

Record: 100

07/22/2015

Company Report

Pages: 32

LPCN Initiation: LPCN 1021, On Track To Become First Oral TRT in $2.5B Market

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 75.00

Research Provided by a Third Party